Orkambi: Company Stock

orkambi: Separate stock market announcements show that he has also sold more than 70m of company stock over the past two years, some or all of it handed to him as part of his pay deals, according to The Guardian. His personal remuneration in 2018 is enough to fund a one-year course of its cystic fibrosis drug Orkambi for 137 patients. A circular to shareholders ahead of the company's upcoming annual meeting showed that Jeff Leiden's deal was 81 times more than the median Vertex employee was paid and an increase on last year's 17.2m deal. Vertex is asking 105,000 per patient per year for the drug, which the NHS insists is not value for money. The NHS last July offered Vertex 500m over five years, with the potential to extend to 10 years and 1bn, for access to Orkambi and other drugs in the pipeline for the disease. There are 10,400 children and young adults with cystic fibrosis in the UK, 40% of whom could benefit from Orkambi. (news.financializer.com). As reported in the news.